- Total Revenues of $423.9 million for the Fourth Quarter of 2022, $1.61 billion for the Full Year 2022 Cabozantinib franchise achieved $1.40 billion in U.S. Net Product Revenues for the Full Year 2022, including $377.4 million for the Fourth Quarter 2022 GAAP Diluted EPS of $(0.09) for the Fourth Quarter of 2.
Drs. Carolyn Bertozzi, Barry Sharpless, and Morten Meldal shared the 2022 Nobel Prize in Chemistry for greatly simplifying the synthesis of complicated molecules. Dr. Bertozzi's protégé writes why her research is so important.
Exelixis (NASDAQ:EXEL – Get Rating) and Qiagen (NYSE:QGEN – Get Rating) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings. Valuation & Earnings This table compares Exelixis and Qiagen’s top-line revenue, earnings […]
/PRNewswire/ Deciduous Therapeutics, an early stage immune therapy start-up, announced today the appointment of an independent board member, additional.